Japan IDE Clinical Study Results: Proven patency in complex SFA lesions.

88% 12-month primary patency in long, complex SFA lesions (n = 103)
- 21.8 cm average lesion length
- 65.7% chronic total occlusions (CTOs)
- 84.5% TASC II C&D lesions

12-Month Patencies:
GORE® VIABAHN® Endoprosthesis Japan IDE Clinical Study*

* GORE® VIABAHN® Endoprosthesis Japan IDE Clinical Study demonstrated 12-month primary patency of 92% as defined by evidence of flow with no Target Lesion Revascularization (TLR). The same study demonstrated 88% 12-month primary patency when defined by PSVR of < 2.5 without a TLR.
**Proven Patency for Complex SFA Lesions.**

359 Limbs Studied

255 CTOs

21 cm Average Lesion Length*

78% Average Primary Patency**

---

**Study** | **Number of Limbs** | **Lesion Length (cm)** | **CTOs (%)** | **12-Month Primary Patency** | **12-Month Secondary Patency**
---|---|---|---|---|---
Japan IDE Clinical Study | 103 | 22 | 66 | 88 | 98
Gore VIPER Clinical Study | 119 | 19 | 56 | 73 | 92
VIASTAR Trial | 66 | 19 | 79 | 78 | 90
25 cm Trial | 71 | 27 | 93 | 67 | 97
**Combined Results** (Weighted average, as appropriate) | 359 | 21 | 70 | 78 | 94

---

* Weighted Average Lesion Length
** 12-Month Weighted Average Primary Patency


---

**INTENDED USE / INDICATIONS:** The GORE® VIABAHN® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery de novo and restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 7.5 mm, and in superficial femoral artery in-stent restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 6.5 mm, and in iliac artery lesions up to 80 mm in length with reference vessel diameters ranging from 4.0 – 12 mm. The GORE® VIABAHN® Endoprosthesis is also indicated for the treatment of stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access grafts. Refer to Instructions for Use at goremedical.com for a complete description of all contraindications, warnings, precautions and adverse events.

Read the Japan IDE Clinical Study Abstract at goremedical.com/viabahn/publications

---

Gore Medical

W. L. Gore & Associates, Inc.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com